Granules India gains on receiving USFDA approval for Metformin ER Tablets

20 Mar 2018 Evaluate

Granules India is currently trading at Rs. 109.20, up by 0.90 points or 0.83% from its previous closing of Rs. 108.30 on the BSE.

The scrip opened at Rs. 108.20 and has touched a high and low of Rs. 109.40 and Rs. 108.20 respectively. So far 4435 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 101.95 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 114.55 and Rs. 107.00 respectively. The current market cap of the company is Rs. 2749.06 crore.

The promoters holding in the company stood at 44.94%, while institutions and non-institutions held 18.36% and 36.70% respectively.

Granules India has received approval from the US Food & Drug Administration (USFDA) for Abbreviated New Drug Application (ANDA) for Metformin Extended Release (ER) Tablets 500 mg and 750 mg. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Glucophage XR tablets of Bristol Myers Squibb. The company intends to commercialize this product shortly.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.